View Older Stories View More Recent Stories
-
Hims and Hers (HIMS) PT Raised at Piper Sandler; 'Another Beat, but Show-Me Story Builds'
-
Hims and Hers (HIMS) PT Raised to $28 at BofA Securities
-
Hims and Hers (HIMS) PT Raised to $38 at TD Cowen
-
Hims and Hers (HIMS) PT Raised to $42 at Leerink Partners
-
Needham on Hims and Hers (HIMS): '2Q Transition Should Not Distract From HIMS Long-Term Trajectory'
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS)
-
Leerink Partners Reiterates Market Perform Rating on Hims and Hers (HIMS)
-
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
-
Morgan Stanley on Hims and Hers (HIMS): 'This marked the first time in the company’s history that next quarter revenue was guided below the Street'
-
Hims & Hers Health, Inc. (HIMS) Misses Q1 EPS by 3c; Issues Mixed Outlook
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.1 calls to1 put into quarter results
-
Hims & Hers is due to report after the bell on Monday. Here's what to expect
-
Hims and Hers (HIMS) New COO 'Logical Hire' - Leerink Partners
-
BofA on Hims and Hers (HIMS), PT $26: 'maintain our Underperform rating given weakening consumer trends and growth rates exiting March'
-
Hims & Hers Health, Inc. (HIMS) Appoints Nader Kabbani as COO
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.6 calls to 1 put into quarter results and outlook
-
Hims & Hers Health, Inc. (HIMS) May 9 weekly 36.50 straddle priced into quarter results
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.8 calls to 1 put on 406K contracts as share price up 24%
-
Piper Sandler Reiterates Neutral Rating on Hims and Hers (HIMS), PT $35, 'Still Struggle to Be Constructive'
-
TD Cowen (which downgraded HIMS yday) Comments on Hims and Hers (HIMS): 'The partnership came as a surprise to us'
-
Hims and Hers (HIMS) PT Raised to $26 at BofA Securities 'and increasing our target EBITDA multiple from 17x to 20- 21x to reflect a longer runway of GLP-1 sales'
-
Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS), PT $40
-
Hims & Hers shares surge over 40% on Wegovy pact with Novo Nordisk
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), 'We think HIMS will not make any margin on dispensing of Wegovy'
-
Hims & Hers Health, Inc. (HIMS) Short Sellers Pressured as Shares Spike Following Novo Nordisk (NVO) Pact
-
Hims & Hers Health, Inc. (HIMS) and Novo Nordisk Team Up to Expand Affordable Access to Care
-
TD Cowen Downgrades Hims and Hers (HIMS) to Hold Citing Lack of NT Catalysts
-
Hims & Hers Health, Inc. (HIMS) Volatile on Martin Shkreli Interview with HIMS YouTuber
-
Hims and Hers (HIMS) PT Lowered to $25 at Citi Amid Valuation Destruction During 2025
-
Hims & Hers Health, Inc. (HIMS) COO to transition into an advisory role
-
BofA Securities on Hims and Hers (HIMS): 'Growth slows in March, but still meaningful upside in 1Q'
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $22
-
Hims and Hers (HIMS) PT Raised to $25 at Jefferies Amid Remarkable Collapse Since February
-
Piper Sandler's Beauty & Wellness Teen Survey: 'Don't See a Beauty Slowdown in Teens'
-
BofA: 'Weekly GLP-1 TRx growth in March is trending slightly ahead of February'
-
Hims & Hers Health, Inc. (HIMS) call put ratio 2.7 calls to 1 put amid as share price down 3.4%
-
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
-
Leerink Cautious on Hims and Hers (HIMS): 'we still have yet to see how the LT growth profile of HIMS' weight loss business can look like'
-
BofA highlights 10 stocks to own for Q2
-
BofA Cautious on Hims and Hers (HIMS): 'HIMS to offer Lilly’s Zepbound, expect minimal revenue contribution'
-
Hims & Hers Health (HIMS) expanding access to personalized weight loss care
-
Hims & Hers Health, Inc. (HIMS) said to sell Lilly's Zepbound
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.7 calls to 1 put
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.1 calls to 1 put amid wide price movement
-
BofA sees 'significant upside' to earnings upside for this popular consumer stock
-
Hims and Hers (HIMS) PT Raised to $22 at BofA Securities, 'execution risk on the top line for a name that has been a beat and raise story since its IPO'
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.2 calls to 1 put amid wide price movement
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $21
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $27, 'highly unlikely that this appeal changes much'
-
DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

